ABM Therapeutics` ABM-1310 Granted Fast Track Designation by the FDA
26 Sep 2023 //
PR NEWSWIRE
ABM Therapeutics begins patient dosing in phase I study of ABM-1310
04 Sep 2023 //
PHARMABIZ
ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310
01 Sep 2023 //
PR NEWSWIRE
ABM Therapeutics doses first patient in Phase I solid tumours trial
05 May 2023 //
CLINICAL TRIALS ARENA
ABM Announces First Patient Dosed in pHI Trial of MEK Inhibitor for Solid Tumor
04 May 2023 //
PR NEWSWIRE
ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310
30 Nov 2021 //
PRNEWSWIRE

Market Place
Sourcing Support